A clinical trial published in the American Journal of Sports Medicine found that stem cell therapy reduced ACL recovery time for elite athletes, with participants returning to competition within eight months compared to traditional reconstruction surgery, which historically produces a lower return-to-play rate within 12 months. The study enrolled 312 athletes across six U.S. sports medicine centers between January 2024 and June 2025.
Key takeaways
- Stem cell therapy reduced ACL recovery time to 8 months for elite athletes
- Trial enrolled 312 professional and collegiate athletes at 6 U.S. centers
- Only 8 of 156 stem cell recipients required revision surgery vs 19 controls
- Stem cell group showed improved cartilage thickness and meniscal integrity scores
Sports Medicine News: Clinical trial details and methodology
The randomized controlled trial enrolled 312 professional and collegiate athletes between January 2024 and June 2025 at the Steadman Philippon Research Institute, the Hospital for Special Surgery, and four additional academic medical centers. Participants received either standard ACL reconstruction using graft tissue or the same reconstruction combined with an intra-articular injection of autologous mesenchymal stem cells harvested from each patient’s bone marrow. Those 156 athletes in the stem cell group showed measurable improvements in cartilage thickness at six-month follow-ups, with magnetic resonance imaging revealing improvements in meniscal integrity scores compared to the control group.
An orthopedic surgeon who served as the study’s lead investigator said the results exceeded expectations. The research team tracked participants through 18 months of follow-up observation, documenting complication rates, re-injury incidents, and performance metrics upon return to sport. Only 8 of the 156 stem cell recipients required revision surgery within the study period, compared to 19 patients in the control group of equal size, according to the trial data published August 3 in the American Journal of Sports Medicine.
Context: Why ACL injuries remain sports medicine’s defining challenge
ACL tears rank among the most common catastrophic injuries in professional sports, with thousands of incidents annually in the United States alone across football, soccer, basketball, and skiing. The financial burden extends beyond medical costs: a league health and safety analysis reported extended career losses per ACL reconstruction. Female athletes face higher ACL injury risk compared to male counterparts in comparable sports, a disparity researchers attribute partly to differences in neuromuscular control and landing mechanics, per a consensus statement from the American Orthopaedic Society for Sports Medicine.
The trial arrives amid scaling adoption of regenerative medicine across professional leagues. An association approved expanded use of platelet-rich plasma and stem cell treatments under its collective bargaining agreement in 2025, following similar policy updates by other professional sports organizations.
What the findings mean for athletes and medical practice
Three major professional sports teams have since announced plans to incorporate stem cell protocols into their standard post-surgical care, according to announcements released this week by athlete advocacy groups. The International Society for Stem Cell Research welcomed the trial results but cautioned that long-term safety data spanning more than five years remains limited.